FMP

FMP

Enter

OYST - Oyster Point Pharma,...

photo-url-https://images.financialmodelingprep.com/symbol/OYST.png

Oyster Point Pharma, Inc.

OYST

NASDAQ

Inactive Equity

As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

11.17 USD

0 (0%)

Latest OYST News

Zacks Investment Research

Nov 10, 2022

OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Read More

Pulse2

Nov 7, 2022

Why Viatris (VTRS) Is Buying Oyster Point (OYST)

Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.

Read More

GlobeNewsWire

Nov 2, 2022

Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022

Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET

Read More

GlobeNewsWire

Sep 27, 2022

Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII

Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research

Read More

GlobeNewsWire

Aug 25, 2022

Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.

Read More

Seeking Alpha

Aug 13, 2022

Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript

Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chief Business Officer Michael Campbell - Senior Vice President and Head of Commercial Conference Call Participants Patrick Dolezal - LifeSci Capital Ken Cacciatore - Cowen Joe Catanzaro - Piper Sandler Daniil Gataulin - Chardan Oper...

Read More

Zacks Investment Research

Aug 11, 2022

OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Read More

GlobeNewsWire

Aug 8, 2022

Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET

Read More

Zacks Investment Research

Jul 21, 2022

Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet

The consensus price target hints at a 423.5% upside potential for OYSTER PT PHARM (OYST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More

Seeking Alpha

Jun 30, 2022

Oyster Therapeutics: State Of Business Is Confounding

OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep